{"id":31214,"date":"2025-12-16T17:14:02","date_gmt":"2025-12-16T16:14:02","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=31214"},"modified":"2025-12-16T17:14:04","modified_gmt":"2025-12-16T16:14:04","slug":"cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/","title":{"rendered":"Cadre d&#8217;action int\u00e9gr\u00e9 de l&#8217;OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l&#8217;h\u00e9patite B et C et les IST, 2026-2030"},"content":{"rendered":"\n<p>L&#8217;Organisation mondiale de la sant\u00e9 (OMS) a publi\u00e9 le Cadre d&#8217;action int\u00e9gr\u00e9 contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l&#8217;h\u00e9patite B et C et les infections sexuellement transmissibles, 2026-2030, une feuille de route historique visant \u00e0 lutter contre la menace croissante de la r\u00e9sistance aux m\u00e9dicaments et \u00e0 pr\u00e9server les progr\u00e8s accomplis dans la lutte contre le sida et les \u00e9pid\u00e9mies d&#8217;h\u00e9patite B, d&#8217;h\u00e9patite C et d&#8217;infections sexuellement transmissibles (IST) en tant que probl\u00e8mes de sant\u00e9 publique.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"587\" height=\"835\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png\" alt=\"\" class=\"wp-image-31215\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png 587w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs-211x300.png 211w\" sizes=\"(max-width: 587px) 100vw, 587px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>Ce document d\u00e9crit une approche mondiale unifi\u00e9e pour lutter contre la r\u00e9sistance aux m\u00e9dicaments, une menace croissante qui risque de compromettre des d\u00e9cennies de progr\u00e8s vers l&#8217;\u00e9radication du sida et des \u00e9pid\u00e9mies d&#8217;h\u00e9patite B, d&#8217;h\u00e9patite C et d&#8217;IST. \u00c9labor\u00e9 \u00e0 l&#8217;issue d&#8217;une consultation large et inclusive, et align\u00e9 sur les strat\u00e9gies mondiales de l&#8217;OMS pour le secteur de la sant\u00e9 et les objectifs de d\u00e9veloppement durable, ce cadre promeut une approche centr\u00e9e sur les personnes et la gestion des antimicrobiens dans cinq domaines cl\u00e9s : <\/p>\n\n\n\n<ul>\n<li>la pr\u00e9vention et la riposte<\/li>\n\n\n\n<li>la surveillance<\/li>\n\n\n\n<li>la recherche et l&#8217;innovation<\/li>\n\n\n\n<li>les capacit\u00e9s des laboratoires<\/li>\n\n\n\n<li>la gouvernance<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-1 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240117204\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le cadre d&#8217;action int\u00e9gr\u00e9<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;Organisation mondiale de la sant\u00e9 (OMS) a publi\u00e9 le Cadre d&#8217;action int\u00e9gr\u00e9 contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l&#8217;h\u00e9patite B et C et les infections sexuellement transmissibles, 2026-2030, une feuille de route historique visant \u00e0 lutter contre la menace croissante de la r\u00e9sistance aux m\u00e9dicaments et \u00e0 pr\u00e9server les progr\u00e8s accomplis dans la [&hellip;]<\/p>\n","protected":false},"author":285,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31,37],"tags":[6697,6607,6733,6698],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cadre d&#039;action int\u00e9gr\u00e9 de l&#039;OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l&#039;h\u00e9patite B et C et les IST, 2026-2030 - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cadre d&#039;action int\u00e9gr\u00e9 de l&#039;OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l&#039;h\u00e9patite B et C et les IST, 2026-2030 - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-16T16:14:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-16T16:14:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png\" \/>\n<meta name=\"author\" content=\"Aurore Brunet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Aurore Brunet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/\"},\"author\":{\"name\":\"Aurore Brunet\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41\"},\"headline\":\"Cadre d&#8217;action int\u00e9gr\u00e9 de l&#8217;OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l&#8217;h\u00e9patite B et C et les IST, 2026-2030\",\"datePublished\":\"2025-12-16T16:14:02+00:00\",\"dateModified\":\"2025-12-16T16:14:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/\"},\"wordCount\":235,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png\",\"keywords\":[\"AMR\",\"Antibior\u00e9sistance\",\"Antibiotic Resistance\",\"Antimicrobial Resistance\"],\"articleSection\":[\"Actualit\u00e9s\",\"Bilans, rapports et recommandations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/\",\"name\":\"Cadre d'action int\u00e9gr\u00e9 de l'OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l'h\u00e9patite B et C et les IST, 2026-2030 - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png\",\"datePublished\":\"2025-12-16T16:14:02+00:00\",\"dateModified\":\"2025-12-16T16:14:04+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Cadre d\u2019action int\u00e9gr\u00e9 de l\u2019OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l\u2019h\u00e9patite B et C et les IST, 2026-2030\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41\",\"name\":\"Aurore Brunet\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cadre d'action int\u00e9gr\u00e9 de l'OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l'h\u00e9patite B et C et les IST, 2026-2030 - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/","og_locale":"fr_FR","og_type":"article","og_title":"Cadre d'action int\u00e9gr\u00e9 de l'OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l'h\u00e9patite B et C et les IST, 2026-2030 - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2025-12-16T16:14:02+00:00","article_modified_time":"2025-12-16T16:14:04+00:00","og_image":[{"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png"}],"author":"Aurore Brunet","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Aurore Brunet","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/"},"author":{"name":"Aurore Brunet","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41"},"headline":"Cadre d&#8217;action int\u00e9gr\u00e9 de l&#8217;OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l&#8217;h\u00e9patite B et C et les IST, 2026-2030","datePublished":"2025-12-16T16:14:02+00:00","dateModified":"2025-12-16T16:14:04+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/"},"wordCount":235,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png","keywords":["AMR","Antibior\u00e9sistance","Antibiotic Resistance","Antimicrobial Resistance"],"articleSection":["Actualit\u00e9s","Bilans, rapports et recommandations"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/","name":"Cadre d'action int\u00e9gr\u00e9 de l'OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l'h\u00e9patite B et C et les IST, 2026-2030 - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png","datePublished":"2025-12-16T16:14:02+00:00","dateModified":"2025-12-16T16:14:04+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/12\/Integrated-drug-resistance-action-framework-for-HIV-hepatitis-B-and-C-and-STIs.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/cadre-daction-integre-de-loms-contre-la-resistance-aux-medicaments-pour-le-vih-lhepatite-b-et-c-et-les-ist-2026-2030\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Cadre d\u2019action int\u00e9gr\u00e9 de l\u2019OMS contre la r\u00e9sistance aux m\u00e9dicaments pour le VIH, l\u2019h\u00e9patite B et C et les IST, 2026-2030"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41","name":"Aurore Brunet"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-15 23:03:07","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31214"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/285"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=31214"}],"version-history":[{"count":1,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31214\/revisions"}],"predecessor-version":[{"id":31217,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31214\/revisions\/31217"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=31214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=31214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=31214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}